Search

Your search keyword '"Koopman, Miriam"' showing total 1,141 results

Search Constraints

Start Over You searched for: Author "Koopman, Miriam" Remove constraint Author: "Koopman, Miriam"
1,141 results on '"Koopman, Miriam"'

Search Results

2. Discovering novel germline genetic variants linked to severe fluoropyrimidine-related toxicity in- and outside DPYD

3. Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: drug screen optimization and correlation with patient response

5. The Trial within Cohorts (TwiCs) study design in oncology: Experience and methodological reflections

9. Dietary and lifestyle inflammation scores in relation to colorectal cancer recurrence and all-cause mortality: A longitudinal analysis

11. Survival of Patients with Deficient Mismatch Repair Versus Proficient Mismatch Repair Metastatic Colorectal Cancer Receiving Curative-Intent Local Treatment of Metastases in a Nationwide Cohort

14. Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis

17. Results from the UNITED study: a multicenter study validating the prognostic effect of the tumor–stroma ratio in colon cancer

21. A tailored approach to horizon scanning for cancer medicines

23. ASO Visual Abstract: Survival of Patients with Deficient Mismatch Repair Versus Proficient Mismatch Repair Metastatic Colorectal Cancer Receiving Curative-Intent Local Treatment of Metastases in a Nationwide Cohort

24. First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group

27. Lymphatic invasion of plakoglobin-dependent tumor cell clusters drives formation of polyclonal lung metastases in colon cancer

28. Long-Term Safety Data on S-1 Administered After Previous Intolerance to Capecitabine-Containing Systemic Treatment for Metastatic Colorectal Cancer

29. Quality of Life and Survival of Metastatic Colorectal Cancer Patients Treated With Trifluridine-Tipiracil (QUALITAS)

31. Serum-based measurements of stromal activation through ADAM12 associate with poor prognosis in colorectal cancer

32. Dietary and lifestyle inflammation scores in relation to colorectal cancer recurrence and all-cause mortality: A longitudinal analysis.

33. Associations between low‐ and high‐fat dairy intake and recurrence risk in people with stage I–III colorectal cancer differ by sex and primary tumour location.

35. Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project

36. Results from the UNITED study: a multicenter study validating the prognostic effect of the tumor–stroma ratio in colon cancer

40. Survival and patient-reported outcomes of real-world high-risk stage II and stage III colon cancer patients after reduction of adjuvant CAPOX duration from 6 to 3 months

41. Efficacy-effectiveness analysis on survival in a population-based real-world study of BRAF-mutated metastatic colorectal cancer patients treated with encorafenib-cetuximab

42. Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis

43. Oncologic outcomes of screen-detected and non-screen-detected T1 colorectal cancers

44. Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: drug screen optimization and correlation with patient response

45. Determinants of Physical Activity among Patients with Colorectal Cancer: From Diagnosis to 5 Years after Diagnosis

46. Improving sustainability of a patient decision aid for systemic treatment of metastatic colorectal cancer: A qualitative study

47. Discovering novel germline genetic variants linked to severe fluoropyrimidine-related toxicity in- and outside DPYD

48. Early evaluation of the effectiveness and cost-effectiveness of ctDNA-guided selection for adjuvant chemotherapy in stage II colon cancer

49. Use of automated assessment for determining associations of low muscle mass and muscle loss with overall survival in patients with colorectal cancer – A validation study

50. Predicting Benefit From FOLFOXIRI Plus Bevacizumab in Patients With Metastatic Colorectal Cancer

Catalog

Books, media, physical & digital resources